Risk factors
Praxis Precision Medicines (PRAX) risk factors
Item 1A of every Praxis Precision Medicines, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks11 new10 dropped20 reworded
Clinical and regulatory risks broaden around side effects, Breakthrough Therapy designations, controlled substances, and accepting foreign trial data.
Filed Feb 19, 2026 - FY2024 10-K risk factors75 risks
Praxis faces heavy risks from its clinical-stage status, ongoing operating losses, and the need for substantial future capital. Commercialization depends entirely on regulatory approvals, patient enrollment, and third-party reimbursement across CNS disorder programs.
Filed Feb 28, 2025